Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 171-187 , June 2003

Current strategies in the management of hormone refractory prostate cancer

References 

  1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 2002;52(1):23–47
  2. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin. Oncol. 1999;26(2):162–173
  3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000; 355(9214): 1491–1498
  4. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J. Clin. Oncol. 1994;12(9):1868–1875
  5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia group B 9182 study. J. Clin. Oncol. 1999;17(8):2506–2513
  6. Smaletz O, Scher HI, Kelly WK, Verbel DA, Regan K, Curley T, et al.  A nomogram for overall survival of patients with castrate-metastatic prostate cancer (PC). Proc. Am. Soc. Clin. Oncol. 2001;20:183a
  7. Small EJ, Halabi S, Picus J, Chen Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc. Am. Soc. Clin. Oncol. 2001;20:174a
  8. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. 2001;61(15):2177–2192
  9. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995;46(2):142–148
  10. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 1999;17(11):3461–3467
  11. Lara PN, Kung HJ, Gumerlock PH, Meyers FJ. Molecular biology of prostate carcinogenesis. Crit. Rev. Oncol. Hematol. 1999;32(3):197–208
  12. Nupponen NN, Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc. Res. Tech. 2000;51(5):456–463
  13. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 1998;153(1):141–148
  14. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, et al.  bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br. J. Cancer. 1996;74(8):1258–1262
  15. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol. 1997;157(2):569–574
  16. Chi SG, de Vere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst. 1994;86(12):926–933
  17. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al.  Alteration of the suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 1995;154(2, Pt 1):414–421
  18. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, de Vere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate. 2002;51(1):59–72
  19. Stearns ME, Wang M. Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol. Oncol. Res. 1994;6(4–5):195–201
  20. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 2001;7(7):1932–1936
  21. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, et al.  Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol. 1997;31(1):1–6
  22. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, et al.  Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene. 2001;20(46):6718–6723
  23. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 1995;55(14):3068–3072
  24. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995;332(21):1393–1398
  25. Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J. Pathol. 1999;187(2):237–241
  26. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol. 2000;164(6):1992–1995
  27. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995;9(4):401–406
  28. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 1996;2(2):277–285
  29. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 1996;2(2):277–285
  30. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, et al.  Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60(4):944–949
  31. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995;332(21):1393–1398
  32. Shi XB, Ma AH, Xia L, Kung HJ, Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002;62(5):1496–1502
  33. George DJ, Kantoff PW. Prognostic indicators in hormone refractory prostate cancer. Urol. Clin. North Am. 1999;26(2):303–310 viii
  34. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J. Clin. Oncol. 1998;16(5):1835–1843
  35. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1993;11(4):607–615
  36. Akimoto S, Inomiya H, Akakura K, Shimazaki J, Ito H. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. Jpn J. Clin. Oncol. 1997;27(4):258–262
  37. Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer. 1993;71(11):3594–3600
  38. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer. 1992;70(12):2870–2878
  39. Akimoto S, Masai M, Akakura K, Shimazaki J. Marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur. Urol. 1995;27(3):207–212
  40. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer: analysis of two Cancer and Leukemia group B studies. Clin. Cancer Res. 1999;5(4):831–837
  41. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J. Clin. Oncol. 1995;13(12):2944–2953
  42. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, et al.  Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J. Clin. Oncol. 2001;19(5):1304–1311
  43. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996;14(6):1756–1764
  44. Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J. Urol. 2000;163(5):1481–1485
  45. Lara PN, Meyers FJ. Treatment options in androgen-independent prostate cancer. Cancer Invest. 1999;17(2):137–144
  46. Fowler JE, Whitmore WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J. Urol. 1981;126(3):372–375
  47. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol. 1993;11(11):2167–2172
  48. Chao D, Harland SJ. The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. Eur. Urol. 1997;31(1):7–10
  49. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, et al.  Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J. Clin. Oncol. 1988;6(9):1456–1466
  50. Fowler JE, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J. Urol. 1995;154(2, Pt 1):448–453
  51. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al.  Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol. 1997;15(8):2928–2938
  52. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur. Urol. 2000;37(2):218–222
  53. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, et al.  High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol. 1998;159(1):149–153
  54. Sinibaldi V, Carducci M, Abeloff M, Eisenberger M. Experience with casodex in patients in patients with stage D3 prostate cancer. Proc. Am. Soc. Clin. Oncol. 1997;16:313a
  55. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 1993;149(3):607–609
  56. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies. Incidence and clinical significance. Drug Safety. 2000;23(5):381–390
  57. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, et al.  Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J. Natl. Cancer Inst. 1994;86(3):222–227
  58. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology. 2001;58(2, Suppl. 1):108–113
  59. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, et al.  A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 1999;5(9):2366–2373
  60. Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, et al.  A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000;88(4):825–834
  61. Chang AY, Bennett JM, Pandya KJ, Asbury R, McCune C. A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am. J. Clin. Oncol. 1989;12(4):358–360
  62. Samojlik E, Lippman AJ, Kirschner MA, Ertel NH, Park Y, Szmal E. Medical adrenalectomy for advanced prostatic cancer: clinical and hormonal effects. Am. J. Clin. Oncol. 1988;11(5):579–585
  63. Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology. 1998;52(2):252–256
  64. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 1995;76(1):96–100
  65. Nishiyama T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int. J. Urol. 1998;5(1):44–47
  66. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, et al.  Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89(12):2570–2576
  67. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol. 1997;15(1):382–388
  68. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, et al.  Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J. Clin. Oncol. 2001;19(1):62–71
  69. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al.  Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N. Engl. J. Med. 1998;339(12):785–791
  70. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, et al.  Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J. Clin. Oncol. 2000;18(21):3595–3603
  71. The FDA safety information and adverse event reporting program. 2002 safety information summaries; 2002
  72. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J. Clin. Oncol. 1989;7(8):1093–1098
  73. Eichenberger T, Trachtenberg J. Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer. Can. J. Surg. 1989;32(5):349–352
  74. Eichenberger T, Trachtenberg J. Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer. Am. J. Clin. Oncol. 1988;11(Suppl. 2):S104–S107
  75. Gerber GS, Chodak GW. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J. Urol. 1990;144(5):1177–1179
  76. Jubelirer SJ, Hogan T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. J. Urol. 1989;142(1):89–91
  77. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 1997;157(4):1204–1207
  78. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997;80(9):1755–1759
  79. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin. Nucl. Med. 2001;31(1):62–68
  80. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J. Urol. 1989;141(1):85–87
  81. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. 2001;165(1):136–140
  82. Dearnaley DP, Sydes MR. On behalf of the MRC PR05 collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. Proc Am Soc Clin Oncol 2001; 20: 174a
  83. Ernst DS, Tannock IF, Venner PM, Winquist EW, Reyno L, Walker H, et al.  Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc. Am. Soc. Clin. Oncol. 2002;21:177a
  84. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2001;345(13):948–955
  85. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin. Oncol. 2001;28(2, Suppl. 6):11–16
  86. Furuya Y, Akakura K, Akimoto S, Ichikawa T, Ito H. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int. J. Urol. 1999;6(4):187–191
  87. Kawakami S, Kawai T, Yonese J, Yamauchi T, Ishibashi K, Ueda T. [Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1993; 84(9): 1681–1684
  88. Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995;33(4):907–912
  89. Kawakami S, Kawai T, Yamauchi T, Yonese J, Ueda T, Ishibashi K. [Palliative radiotherapy for bone pain in hormone refractory prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1993; 84(10): 1791–1796
  90. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995;274(5):420–424
  91. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al.  A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol. 1994;31(1):33–40
  92. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1993;25(5):805–813
  93. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, et al.  Samarium-153-EDTMP in bone metastases. J. Nucl. Biol. Med. 1994;38(4, Suppl. 1):123–127
  94. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al.  Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J. Nucl. Med. 1993;34(11):1839–1844
  95. Sandeman TF, Budd RS, Martin JJ. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin. Oncol. (R Coll. Radiol.). 1992;4(3):160–164
  96. Roth BJ. Androgen-independent prostate cancer: not so chemorefractory after all. Semin. Oncol. 1999;26(6, Suppl. 18):43–50
  97. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71(3, Suppl.):1098–1109
  98. Smith DC, Jodrell DI, Egorin MJ, Ambinder RM, Zuhowski EG, Kreis W, et al.  Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemother. Pharmacol. 1993;31(5):363–368
  99. Williamson SK, Wolf MK, Eisenberger MA, O’Rourke MA, Brannon W, Crawford ED. Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Am. J. Clin. Oncol. 1996;19(4):368–370
  100. van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schroder FH, Mickisch GH. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol. 2000;45(6):509–512
  101. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer. 1994;74(1):100–103
  102. Schmid HP, Maibach R, Bernhard J, Hering F, Hanselmann S, Gusset H, et al.  A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer. 1997;79(9):1703–1709
  103. Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thurlimann B, et al.  Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 2000;11(2):183–188
  104. Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest. New Drugs. 1998;16(4):353–359
  105. Witte RS, Yeap BY, Trump DL. Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial. Invest. New Drugs. 1994;12(3):255–258
  106. Rajagopalan K, Peereboom D, Budd GT, Olencki T, Murthy S, Elson P, et al.  Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer. Invest. New Drugs. 1998;16(3):255–258
  107. Atkins JN, Muss HB, Case LD, Richards F, Grote T, McFarland J. Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Am. J. Clin. Oncol. 1996;19(1):23–25
  108. Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, et al.  5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am. J. Clin. Oncol. 1998;21(2):171–176
  109. Huan SD, Aitken SE, Stewart DJ. 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study. Ann. Oncol. 1994;5(7):644–645
  110. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, et al.  A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993;72(6):1965–1968
  111. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs. 2000;11(2):123–127
  112. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, et al.  Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest. New Drugs. 1995;13(3):235–240
  113. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J. Clin. Oncol. 1996;14(5):1617–1625
  114. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am. J. Clin. Oncol. 1999;22(5):471–474
  115. Naito S, Ueda T, Kotoh S, Kumazawa J, Itoh K, Sagiyama K, et al.  Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. Cancer Chemother. Pharmacol. 1995;35(3):225–229
  116. Fuse H, Muraishi Y, Fujishiro Y, Katayama T. Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer. Int. Urol. Nephrol. 1996;28(1):79–85
  117. von Roemeling R, Fisher HAG, Horton J. Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: a ph-I/II pilot study. Proc. Am. Soc. Clin. Oncol. 1992;11:213
  118. Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, et al.  Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br. J. Urol. 1993;72(5, Pt 1):625–628
  119. Ukimura O, Kamoi K, Hongo F, Nakao M, Mizutani Y, Nishimura K, et al.  Oral administration of dexamethasone in combination with UFT and cyclophosphamide for the treatment of hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:165b
  120. Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer. 1996;77(6):1144–1148
  121. Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer. 1993;71(12):3975–3978
  122. Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, Larrimer NR. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur. J. Cancer. 1992;28(2–3):477–478
  123. Raghavan D, Coorey G, Rosen M, Page J, Farebrother T. Management of hormone-resistant prostate cancer: an Australian trial. Semin. Oncol. 1996;23(6, Suppl. 14):20–23
  124. Otto T, Rembrink K, Goepel M, Krege S, Meyer-Schwiekerath M, Rubben H. [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study]. Urologe A 1996; 35(2): 142–145
  125. Kantoff PW, Block C, Letvak L, George M. 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am. J. Clin. Oncol. 1993;16(6):489–491
  126. Kozloff M, Robin EL, Raminski D, Rao Uppuluri VS, Sylora J, Starr A, et al.  A phase II study using mitoxantrone and ketoconazole in hormone resistant metastatic adenocarcinoma of the prostate. Proc. Am. Soc. Clin. Oncol. 2001;20:153b
  127. Stearns ME, Tew KD. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J. Cell Sci. 1988;89(Pt 3):331–342
  128. Hartley-Asp B, Natale RB, Dreicer R, Falcon S, Ricardez A, Redfern C, et al.  Phase II study of weekly intravenous (IV) estramustine phosphate (EMP IV) 2000mg/m2 in patients with hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2001;20:183a
  129. Morote J, Lopez-Pacios MA, Ahmad A, Vila J, De Torres JA. [Treatment of hormone-refractory prostate cancer with estramustine phosphate]. Actas Urol Esp 1991; 15(5): 421–424
  130. Tanaka M, Shiomi K, Hamano S, Suzuki N, Igarashi T, Murakami S, et al. [Effect of estramustine phosphate on hormone refractory prostate cancer]. Hinyokika Kiyo 1997; 43(3): 245–250
  131. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al.  Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J. Urol. 1997;157(3):929–934
  132. de Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology. 1988;31(4):312–317
  133. Loening SA, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, et al.  Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J. Urol. 1983;129(5):1001–1006
  134. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al.  Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology. 1997;50(5):754–758
  135. Sumiyoshi Y, Hashine K, Nakatsuzi H, Yamashita Y, Karashima T. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. Int. J. Urol. 2000;7(7):243–247
  136. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al.  Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. 1994;12(10):2005–2012
  137. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, et al.  A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology. 1997;50(3):401–406
  138. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, et al.  A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate. 2001;46(4):257–261
  139. Soloway MS, Dekernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, et al.  Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J. Urol. 1981;125(5):664–667
  140. Awakura Y, Yamamoto M, Fukuzawa S, Itoh N, Nonomura M, Fukuyama T. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer]. Hinyokika Kiyo 2000; 46(7): 449–452
  141. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 1992;10(11):1754–1761
  142. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 1992;147(3, Pt 2):931–934
  143. Sella A, Flex D, Konichezky M, Sulkes A, Baniel J. Combination chemotherapy following adrenal suppression in androgen-independent prostate cancer. Eur. Urol. 2000;38(3):255–258
  144. Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero JM, Arcusa A, et al.  Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol. 1998;37(2):187–191
  145. Pienta KJ, Olson KB. Treatment of metastatic hormone refractory prostate cancer with estramustine (emcyt) and vinorelbine. Proc. Am. Soc. Clin. Oncol. 2001;20:168b
  146. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, et al.  Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am. J. Clin. Oncol. 1997;20(4):383–386
  147. Hudes G, Ross E, Roth B, Balshem A, Loehrer PJ, Ramsey H, et al.  Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate. Proc. Am. Soc. Clin. Oncol. 2002;21:177a
  148. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72(8):2457–2460
  149. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, et al.  Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000;89(2):431–436
  150. Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, et al.  Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol. 1995;22(5, Suppl. 12):41–45
  151. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al.  Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1997;15(9):3156–3163
  152. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, et al.  Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001;58(1):59–64
  153. Athanasiadis A, Tsavdaridis D, Athanassiades I, Pergantas N, Roussos G, Rigatos SK, et al.  Paclitaxel (P) and estramustine phosphate (EP) in patients with hormone refractory prostate cancer (HRPC)—a phase II study. Proc. Am. Soc. Clin. Oncol. 2001;20:189a
  154. Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, et al.  A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer. 2001;91(11):2039–2045
  155. Vaishampayan UN, Fontana JA, Hussain M. An active regimen of weekly estramustine and paclitaxel in metastatic androgen independent (AI) prostate cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:188a
  156. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 1999;17(6):1664–1671
  157. Friedland D, Cohen J, Miller R, Voloshin M, Gluckman R, Lembersky B, et al.  A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumour effect to phosphorylation of Bcl-2. Semin. Oncol. 1999;26(5, Suppl. 17):19–23
  158. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. 1999;26(5, Suppl. 17):14–18
  159. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin. Oncol. 2001;28(4, Suppl. 15):8–15
  160. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel (TAXOTERE) in hormone refractory metastatic prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2000;19:348a
  161. Petrylak DP, Macarthur RB, O’Connor J, Shelton G, Judge T, Balog J, et al.  Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 1999;17(3):958–967
  162. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann. Oncol. 1999;10(1):33–38
  163. Copur MS, Tarantolo SR, Hauke R, Ledakis P, Lynch JC, Bolton M, et al.  Weekly estramustine (E) taxotere (T) and dexamethasone (D) in patients with hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2000;19:347a
  164. Kosty MP, Ferreira A, Bryntesen T, Grossman J. Weekly docetaxel and low-dose estramustine phosphate in hormone-refractory prostate cancer: a phase II study. Proc. Am. Soc. Clin. Oncol. 2000;19:365a
  165. Petrylak DP, Shelton GB, England-Owen C, Pfaff C, Bagliella E, Diuleo R, et al.  Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (pts) with androgen-independent prostate cancer (AIPCA). Proc. Am. Soc. Clin. Oncol. 2000;19:334a
  166. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of. Cancer and Leukemia Group B CALGB 9780. J. Clin. Oncol. 2001;19(9):2509–2516
  167. Sinibaldi VJ, Eisenberger MA. Preliminary evaluation of docetaxel plus 1-day estramustine in the treatment of prostate cancer. Advances in Prostate Cancer. 2000;4:8–10
  168. Sitka CM, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, et al.  Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin. Oncol. 2001;28(4, Suppl. 15):16–21
  169. Casciano R, Petrylak D, Neugut AI, Doyle J, Casciano J, Arikian S, et al.  Systematic review of chemotherapy efficacy from controlled trials in hormone-refractory prostate cancer (HRPC) patients. Proc. Am. Soc. Clin. Oncol. 2001;20:169b
  170. Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin. Oncol. 1999;26(5, Suppl. 17):55–60
  171. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology. 2002;16(6, Suppl. 6):63–72
  172. Hwang LC, Fein S, Levitsky H, Nelson WG. Prostate cancer vaccines: current status. Semin. Oncol. 1999;26(2):192–201
  173. Lara PN, Meyers FJ, Gray CR, Gandour Edwards R, Gumerlock PH, Kauderer C, et al.  HER-2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the California Cancer Consortium screening trial. Cancer. 2002;94:2584–2589
  174. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al.  Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res. 1996;2(8):1289–1297
  175. O’Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, et al.  Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. 2001;7(6):1561–1568
  176. Schellhammer P, Small EJ, Higano CS, Neumunaitis J, Peshwa M, Jones L, et al.  Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: a phase III randomized, double blind, placebo controlled trial. Proc. Am. Soc. Clin. Oncol. 2002;21:183a
  177. Li Y, Chinni SR, Senderowicz AM, Sarkar FH. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int. J. Oncol. 2000;17(4):755–759
  178. Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin. Oncol. 2001;28(4, Suppl. 15):56–61
  179. Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken I, et al.  Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. 2001;166(3):882–886
  180. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–2333
  181. Carducci MA, Nelson JB, Padley RJ, Janus T, Hippensteel R. The endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a multinational, randomized, double-blind, placebo-controlled trial. Proc. Am. Soc. Clin. Oncol. 2001;20:174a
  182. Logothetis CJ, Yang H, Daliani D, Millikan RE, Tu S, Pagliaro L, et al.  Dose dependent inhibition of 20S proteasome results in serum Il-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc. Am. Soc. Clin. Oncol. 2001;20:186a
  183. Gumerlock PH, Lara PN, Gandara DR. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increased response in non small cell carcinoma (NSCLC). Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001; 157
  184. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 2001;7(12):3920–3927
  185. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 2001;7(7):1888–1893
  186. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al.  A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. Oncol. 2001;28(4, Suppl. 15):62–66
  187. Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, et al.  Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 2001;20:174a
  188. Heath EI, Grochow LB. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000;59(5):1043–1055

PII: S0305-7372(02)00090-7

doi: 10.1016/S0305-7372(02)00090-7

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 171-187 , June 2003

Article Tools

* Image Usage & Resolution